Signatera™ for Pancreatic Cancer

Signatera™ is a tumor-informed ctDNA assay for pancreatic cancer, monitoring MRD from the post-surgical window through long-term surveillance. Post-surgical MRD positivity predicted dramatically inferior disease-free survival; in multivariate analysis, MRD status was the only independent predictor of recurrence — outperforming CA 19-9, KRAS, and stage.¹

Order Signatera™ test

Inform clinical challenges in pancreatic cancer

Signatera™-positivity

post-surgery linked to

5.5x

higher recurrence risk; median DFS 6.4 vs 33.3 months.¹

Signatera™-positive

patients during surveillance had a median DFS of

11.4

months. In multivariate analysis, Signatera™ was the strongest predictor of recurrence (HR=24.28).¹

Signatera™ detected

recurrence a mean of

>101

days before imaging.¹

Post-surgical Signatera™ positivity identified the highest risk patients¹

In the largest real-world, personalized tumor-informed ctDNA analysis in pancreatic cancer to date, Botta et al. analyzed 1,329 plasma samples from 298 clinically patients with PDAC

Signatera™ positivity in the MRD window was associated with significantly inferior disease-free survival — median 6.4 vs 33.3 months.¹

Read publication

SGN_WB_MD_PDAC_20260327_NAT-8023566_TextImage (1)

SGN_WB_MD_PDAC_20260327_NAT-8023566_TextImage2 (1)

Identify recurrence sooner with Signatera™

During surveillance, median disease-free survival was 11.4 months in Signatera™-positive patients and not reached in Signatera™-negative patients.¹

Signatera™-positivity in surveillance outperformed CA19-9, KRAS, and stage in pancreatic cancer

In multivariate analysis of resected stage I–III PDAC, Signatera™ status was the only independent predictor of DFS.¹

Is Signatera™ for Pancreatic cancer right for your patients?

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Botta M, et al. Tumor-informed ctDNA predicts recurrence and survival in resected pancreatic cancer. The Oncologist. 2024. DOI: 10.1093/oncolo/oyae155